Found 22 resultsAuthor [ Title] Type Year
Filters: Author is Bailer, Robert T [Clear All Filters]
Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med, 376(10), 928-938. presented at the 2017 03 09. doi:10.1056/NEJMoa1410863. (2017).
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One, 10(5), e0125914. presented at the 2015. doi:10.1371/journal.pone.0125914. (2015).
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One, 8(4), e59340. presented at the 2013. doi:10.1371/journal.pone.0059340. (2013).
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS One, 13(11), e0206837. presented at the 2018. doi:10.1371/journal.pone.0206837. (2018).
Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial. PLoS One, 9(9), e106240. presented at the 2014. doi:10.1371/journal.pone.0106240. (2014).
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis, 194(12), 1638-49. presented at the 2006 Dec 15. doi:10.1086/509258. (2006).
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis, 194(12), 1650-60. presented at the 2006 Dec 15. doi:10.1086/509259. (2006).
Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One, 10(4), e0123969. presented at the 2015. doi:10.1371/journal.pone.0123969. (2015).
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine, 25(20), 4085-92. presented at the 2007 May 16. doi:10.1016/j.vaccine.2007.02.050. (2007).
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). PLoS One, 9(3), e91366. presented at the 2014. doi:10.1371/journal.pone.0091366. (2014).
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis, 208(3), 418-22. presented at the 2013 Aug 01. doi:10.1093/infdis/jit180. (2013).
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One, 5(2), e9015. presented at the 2010 Feb 02. doi:10.1371/journal.pone.0009015. (2010).
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV, 6(5), e297-e306. presented at the 2019 05. doi:10.1016/S2352-3018(19)30053-0. (2019).
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis, 211(4), 549-57. presented at the 2015 Feb 15. doi:10.1093/infdis/jiu511. (2015).
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, 385(9977), 1545-54. presented at the 2015 Apr 18. doi:10.1016/S0140-6736(14)62385-0. (2015).
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS One, 14(9), e0222178. presented at the 2019. doi:10.1371/journal.pone.0222178. (2019).
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One, 5(9), e12873. presented at the 2010 Sep 21. doi:10.1371/journal.pone.0012873. (2010).
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, 384(9959), 2046-52. presented at the 2014 Dec 06. doi:10.1016/S0140-6736(14)61185-5. (2014).
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.. Vaccine, 25(8), 1513-25. presented at the 2007 Feb 09. doi:10.1016/j.vaccine.2006.10.047. (2007).
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 26(50), 6338-43. presented at the 2008 Nov 25. doi:10.1016/j.vaccine.2008.09.026. (2008).
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis, 207(12), 1829-40. presented at the 2013 Jun 15. doi:10.1093/infdis/jit098. (2013).
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis, 203(10), 1396-404. presented at the 2011 May 15. doi:10.1093/infdis/jir054. (2011).